NanoString Technologies to Release Fourth Quarter and Fiscal Year 2017 Financial Results and Host Conference Call on Wednesda...
February 21 2018 - 6:00AM
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life
science tools for translational research and molecular diagnostic
products, today announced that the Company will release fourth
quarter and fiscal year 2017 financial results after the close of
trading on Wednesday, March 7, 2018. Company management will host a
conference call beginning at 4:30pm ET to discuss those results and
provide a business update.
Individuals interested in listening to the
conference call may do so by dialing (888) 793-9492 for domestic
callers, or (734) 385-2643 for international callers. Please
reference Conference ID: 5389066. To listen to a live webcast,
please visit the investor relations section of the company’s
website at nanostring.com.
A replay of the call will be available beginning
March 7, 2018 at 7:30pm ET through midnight on March 14, 2018. To
access the replay, dial (855) 859-2056 or (404) 537-3406 and
reference Conference ID: 5389066. The webcast will also be
available on the Company’s website for one year following the
completion of the call.
About NanoString Technologies, Inc.NanoString
Technologies provides life science tools for translational research
and molecular diagnostic products. The company's nCounter Analysis
System has been employed in life sciences research since it was
first introduced in 2008 and has been cited in more than 1,830
peer-reviewed publications. The nCounter Analysis System offers a
cost-effective way to easily profile the expression of hundreds of
genes, proteins, miRNAs, or copy number variations, simultaneously
with high sensitivity and precision, facilitating a wide variety of
basic research and translational medicine applications, including
biomarker discovery and validation. The company's technology is
also being used in diagnostics. The Prosigna® Breast Cancer
Prognostic Gene Signature Assay together with the nCounter Dx
Analysis System is FDA 510(k) cleared for use as a prognostic
indicator for distant recurrence of breast cancer. In addition, the
company is collaborating with multiple biopharmaceutical companies
in the development of companion diagnostic tests for various cancer
therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
Contact:Doug FarrellVice President, Investor
Relations & Corporate
Communicationsdfarrell@nanostring.comPhone: 206-602-1768
NanoString Technologies (NASDAQ:NSTG)
Historical Stock Chart
From Apr 2024 to May 2024
NanoString Technologies (NASDAQ:NSTG)
Historical Stock Chart
From May 2023 to May 2024